Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

This was the stock's third consecutive day of losses.

Amgen Inc. (NASDAQ:AMGN) is one of the top low volatility healthcare stocks to buy now. On July 23, BofA analyst Tim Anderson ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Topline The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the ...

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Amgen won FDA approval for a cancer immunotherapy made from a genetically modified form of the cold sore virus. Here's how the drug could contribute to the rapidly growing field of immuno-oncology.

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.